Optimizing care for MRKH patients: From malformation screening to uterus transplantation eligibility
Acta Obstetricia et Gynecologica Scandinavica · 2025
DOI: 10.1111/aogs.14985 ↗At a glance
Journal article in Acta Obstetricia et Gynecologica Scandinavica, 2025. Written by Auriane Cospain and 17 co-authors. Institution: Clinical Genetics Department, CLAD Ouest CRDI, ERN ITHACA, Rennes University Hospital, Rennes, France. Major MEDLINE topics: 46, XX Disorders of Sex Development, Mullerian Ducts, Uterus, Congenital Abnormalities. Cited 6 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Introduction
Mayer‐Rokitansky‐Küster‐Hauser (MRKH) syndrome with utero‐vaginal aplasia is the most severe form of the Müllerian duct anomalies and can be associated with extra‐genital abnormalities such as renal or skeletal anomalies, hearing loss, or cardiac defects. The past two decades have witnessed significant advances both in understanding the etiologies of MRKH and in the development of fertility treatments such as uterine transplantation. The present work aimed to determine the rate of women with MRKH syndrome who underwent optimal initial management (after comprehensive malformation assessment) and to establish the rate of patients eligible for uterine transplantation (i.e., those with a vaginal length ≥7 cm without reconstruction using a bowel segment, and an anti‐Müllerian hormone level >1.5 ng/mL before 35 years). Material and Methods Cohort study of 85 women with MRKH syndrome consulting in our tertiary center.
Results
62.4% of women with MRKH syndrome had an exhaustive malformative evaluation according to the French guidelines (Protocole National de Diagnostic et de Soin [PNDS]), of which 76.5% had associated malformations (MRKH type II). Pedigree, when available, showed a family history of infertility or a urogenital tract spectrum anomaly in 60% of cases. Concerning the uterine transplantation selection criteria, when evaluated, 22.6% of women had an anti‐Müllerian hormone level
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Clinical Genetics Department, CLAD Ouest CRDI, ERN ITHACA, Rennes University Hospital, Rennes, France.
- Cytogenetics and Cell Biology Department, Rennes University Hospital, Rennes, France.
- Gynecology Department, Rennes University Hospital, Rennes, France.
- Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Rennes, France.
- Medically assisted reproduction Department, Clinique Mutualiste La Sagesse, Rennes, France.
- Anatomy and Pathological Cytology, Rennes University Hospital, Rennes, France.
ORCID profiles: Auriane Cospain, Isis Carton
Cite
APA
Cospain, A., Dion, L., Bidet, M., Nyangoh Timoh, K., Quelin, C., Carton, I., Lavillaureix, A., Morcel, K., Rollier, P., Pasquier, L., Nouyou, B., Odent, S., Guerrier, D., Launay, E., Belaud Rotureau, M. A., Fradin, M., Jaillard, S., & Lavoué, V. (2025). Optimizing care for MRKH patients: From malformation screening to uterus transplantation eligibility. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.14985
Vancouver
Cospain A, Dion L, Bidet M, Nyangoh Timoh K, Quelin C, Carton I, et al. Optimizing care for MRKH patients: From malformation screening to uterus transplantation eligibility. Acta Obstetricia et Gynecologica Scandinavica. 2025. doi:10.1111/aogs.14985
BibTeX
@article{Cospain2025,
author = {Cospain, Auriane and Dion, Ludivine and Bidet, Maud and Nyangoh Timoh, Krystel and Quelin, Chloé and Carton, Isis and Lavillaureix, Alinoe and Morcel, Karine and Rollier, Paul and Pasquier, Laurent and Nouyou, Bénédicte and Odent, Sylvie and Guerrier, Daniel and Launay, Erika and Belaud Rotureau, Marc-Antoine and Fradin, Mélanie and Jaillard, Sylvie and Lavoué, Vincent},
title = {Optimizing care for MRKH patients: From malformation screening to uterus transplantation eligibility},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2025},
doi = {10.1111/aogs.14985}
}
EUVIMED